title: Evidence for functionally distinct subclasses of gamma-aminobutyric acid receptors in rabbit retina.
abstract: gamma-Aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the mammalian retina, where it serves many roles in establishing complex response characteristics of ganglion cells. We now provide biochemical and physiological evidence that at least three subclasses of GABA receptors (A1, A2, and B) contribute to different types of synaptic integration. Receptor binding studies indicate that approximately three-fourths of the total number of [3H]GABA binding sites in retina are displaced by the GABAA receptor antagonist, bicuculline, whereas one-fourth are displaced by the GABA-B receptor agonist, baclofen. GABAA receptors can be described by a three-site binding model with KD values of 19 nM, 122 nM, and 5.7 microM. Benzodiazepines and barbiturates potentiate binding to the GABAA site, which suggests that significant numbers of GABAA receptors are coupled to regulatory sites for these compounds and thus are classified as GABAA1 receptors. The response to pentobarbital appears to involve a conversion of low-affinity sites to higher-affinity sites, and is reflected in changes in the densities of sites at different affinities. Functional studies were used to establish which of the different receptor subclasses regulate release from cholinergic amacrine cells. Our results show that GABA suppresses light-evoked [3H]acetylcholine release via GABAA2 receptors not coupled to a benzodiazepine or barbiturate regulatory site, and enhances release via GABAB receptors. GABAA1 sites do not appear to control acetylcholine release in rabbit retina.
authors.affiliation: Department of Neurobiology and Anatomy, University of Texas Medical School, Houston 77225.
authors.forename: D L
authors.initials: DL
authors.lastname: Friedman
authors.forename: D A
authors.initials: DA
authors.lastname: Redburn
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000596:Amino Acids / Q000494:pharmacology; D021542:Amino Acids, Neutral; D000818:Animals; D001418:Baclofen / Q000494:pharmacology; D001667:Binding, Competitive; D002458:Cell Fractionation; D005479:Flurazepam / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D008027:Light; D008962:Models, Theoretical; D010424:Pentobarbital / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D011817:Rabbits; D011963:Receptors, GABA-A / Q000187:drug effects / Q000302:isolation & purification / Q000378:metabolism*; D012160:Retina / Q000187:drug effects / Q000378:metabolism*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D000109:Acetylcholine; D000596:Amino Acids; D021542:Amino Acids, Neutral; D001418:Baclofen; D005479:Flurazepam; D010424:Pentobarbital; D010852:Picrotoxin; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; C013809:5-aminovaleric acid